UIC conducts phase I drug study for advanced pancreatic cancer

June 3, 2014, University of Illinois at Chicago

Researchers at the University of Illinois at Chicago are conducting a clinical trial to evaluate a new, three-drug combination therapy for advanced pancreatic cancer.

Pancreatic ductal carcinoma has a five-year survival rate of less than 5 percent and is the fourth-leading cause of in the U.S., claiming nearly 40,000 lives each year.

Scientists have made some progress in the last decade to understand the biology of the disease at the cellular level, but advances in clinical outcomes have not kept pace.

"There is an urgent and unmet need for effective treatments for patients with advanced after first-line chemotherapy fails," said Dr. Neeta Venepalli, UIC assistant professor of hematology and principal investigator of the study.

Patients in the phase 1 study will be given three drugs that are thought to attack the in different ways. One, gemcitabine, is an FDA-approved chemotherapy drug that works by slowing or stopping the growth of tumors. It has been the standard treatment for advanced pancreatic cancer for the past decade.

A second drug, a monoclonal antibody that recognizes a protein called mucin 1 that prevents the death of cancer cells and is overabundant in pancreatic ductal carcinoma, is given to patients to stimulate an immune response. The antibody also attracts the third drug, Imprime PGG, which travels to the tumor site to activate an and kill targeted cancer cells.

"Our phase 1 trial combines gemcitabine with two novel cancer immunotherapies – a regimen that has not been tried before," said Venepalli, a member of the UI Cancer Center.

"We are optimistic and excited about providing a new approach to treating this devastating disease."

The study will evaluate the combination to determine the highest dose of the monoclonal antibody that can be tolerated without unacceptable side effects.

The monoclonal antibody and Imprime PGG are investigational drugs and will be provided by Biothera, a U.S. biotechnology company.

Explore further: Scientists discover new route to boost pancreatic cancer treatment

Related Stories

Scientists discover new route to boost pancreatic cancer treatment

May 30, 2014
Cancer Research UK scientists have uncovered new insights into how a key pancreatic cancer drug – gemcitabine – is broken down in tumour cells, according to research* published in the British Journal of Cancer (BJC), ...

Radioimmunotherapy, Gemcitabine combination shows early promise for metastatic pancreatic ductal cancer

May 20, 2014
A combination of several small doses of an investigational radioimmunotherapy and the chemotherapy gemcitabine had superior outcomes compared with radioimmunotherapy alone in patients with metastatic pancreatic ductal cancer, ...

New type of immunotherapy shows potential in advanced lung cancer

January 8, 2014
(Medical Xpress)—When added to chemotherapy and antibody therapy, Imprime PGG, a type of immunotherapy, substantially improved response rates and overall survival rates in patients with late-stage, non-small cell lung cancer ...

Phase I study of DMOT4039A in patients with pancreatic or ovarian cancer

May 30, 2014
A study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) describes the results of a phase I clinical trial of the investigational agent DMOT4039A against pancreatic and ovarian cancers. ...

Antibody-drug conjugate may provide new treatment option for pancreatic cancer patients

October 21, 2013
Patients with pancreatic cancer may benefit from an investigational member of an emerging class of anticancer drugs called antibody-drug conjugates, according to preclinical results presented here at the AACR-NCI-EORTC International ...

Clinical trial looks to improve pancreatic cancer survival rates

February 12, 2013
Researchers at Georgia Regents University Cancer Center are investigating a new avenue of treatment to help boost poor pancreatic cancer survival rates.

Recommended for you

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.